You searched for stem cell therapy - Page 83 of 87

Hateful politics infiltrate human genome editing debate in France

June 27, 2016 / Professor Paul Knoepfler, Ph.D. / 1 Comment

By Elliot Hosman Summary. A campaign calling for a moratorium on using CRISPR in human embryos was launched by a prominent French organization fighting for narrow understandings of life and family. A recent campaign calling for a ban on “transgenic” human embryos was launched by one of France’s most prominent organizations fighting for “science”-backed “one-man-one-woman” […]

Hateful politics infiltrate human genome editing debate in France Read More »

New Herbert lab Nature paper reinforces mitochondrial replacement Achilles heel

June 8, 2016 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Today a new Nature paper from Dr. Mary Herbert’s group in the UK has found a key problem with mitochondrial replacement therapy that fits with data from others. Mitochondrial replacement data The goal of preventing mitochondrial disease using various kinds of genome transfer technologies is a noble one, but mitochondrial replacement therapy has faced a

New Herbert lab Nature paper reinforces mitochondrial replacement Achilles heel Read More »

UC Davis CRISPR Meeting Panel: A View from the Trenches on Human Disease

May 26, 2016 / Professor Paul Knoepfler, Ph.D. / 3 Comments

The second session at our CRISPR meeting was really powerful. As with other posts from the UC Davis CRISPR meeting, since I was taking notes on the fly during this session, this post is a stream of bits from the different talks, often trying to capture the essence of key questions or ideas as the speakers

UC Davis CRISPR Meeting Panel: A View from the Trenches on Human Disease Read More »

UK should freeze mitochondrial replacement as Egli paper ID’s serious problem

May 19, 2016 / Professor Paul Knoepfler, Ph.D. / 1 Comment

An important new Cell Stem Cell paper from Dieter Egli’s lab points to an inherent, serious problem with so-called 3-person IVF or mitochondrial replacement technology that warrants putting an immediate hold on all efforts to use it in humans. I have pasted the graphical abstract from the paper below. For years a few of us scientists and

UK should freeze mitochondrial replacement as Egli paper ID’s serious problem Read More »

In Depth Report from April 29th Paris Human Gene Editing Meeting

May 11, 2016 / Professor Paul Knoepfler, Ph.D.

Editor’s note. Caroline Simons attended both the April 28th (see her report on that here) and 29th Paris meetings on human gene editing/genetic modification. Today, we have her in depth report on the April 29th meeting. I have posted her piece in full with only minor edits. If you are in a rush you can

In Depth Report from April 29th Paris Human Gene Editing Meeting Read More »

Paris human gene editing workshop summary

April 29, 2016 / Professor Paul Knoepfler, Ph.D.

Editors note: This is a guest post from Caroline Simons who is attending the two Paris meetings on human gene editing. For more background on those meetings see here. By Caroline Simons There were just over a hundred participants at the workshop organized by the Federation of European Academies of Medicine, the UK Academy of

Paris human gene editing workshop summary Read More »

George Church chat: CRISPR people, Zika, weapons

April 18, 2016 / Professor Paul Knoepfler, Ph.D. / 4 Comments

I talked last year about human genetic modification by CRISPR with George Church a year ago. Now we’ve followed up with a long chat on this topic going into much more detail and with questions on recent developments. Each question is listed numerically and then there is a back and forth on that question with George

George Church chat: CRISPR people, Zika, weapons Read More »

Poll: How do you feel about pay-to-play clinical trials?

March 30, 2016 / Professor Paul Knoepfler, Ph.D. / 15 Comments

6a00e55417fcfd8834014e869e537f970d-600wi

There’s a growing trend whereby patients have to pay to be in a clinical trial, which are called pay-to-play clinical trials. Proponents of this idea point toward potential benefits in the form of patients gaining access to innovative therapies. They also argue that this approach provides a much-needed funding mechanism for the trials and that

Poll: How do you feel about pay-to-play clinical trials? Read More »

ViaCyte on the Rise: First Diabetes Trial Data & Acquires BetaLogics IP

February 4, 2016 / Professor Paul Knoepfler, Ph.D.

VC-01-post-implant-final1-e1503703572933, viacyte

Clinical research on Type I Diabetes is one of the most exciting and promising areas of stem cells and regenerative medicine for human disease. Two of the coolest companies out there in this arena have been ViaCyte and BetaLogics (owned by J&J). For more on ViaCyte see my interview with President and CEO Paul Laikind

ViaCyte on the Rise: First Diabetes Trial Data & Acquires BetaLogics IP Read More »

NAS proposes prudent US policy on 3-person IVF

February 3, 2016 / Professor Paul Knoepfler, Ph.D. / 3 Comments

A new report from the National Academies of Sciences (NAS), Engineering, and Medicine here in the US recommends a policy significantly more cautious on first read for 3-person IVF than that in place now in the UK. My initial take on this new 164-page report is that it is very well thought out and the

NAS proposes prudent US policy on 3-person IVF Read More »

Search Results for: stem cell therapy